Nucana announces encouraging initial data from phase 1b/2 modular study of nuc-3373 in combination with pembrolizumab or docetaxel

Patients with advanced solid tumors who had exhausted all other treatment options and were pd-(l)1 experienced achieved significant tumor volume reductions and prolonged progression free survival following treatment with nuc-3373 plus pembrolizumab
NCNA Ratings Summary
NCNA Quant Ranking